2496 — Wuhan YZY Biopharma Co Income Statement
0.000.00%
Last trade - 00:00- HK$1.44bn
- HK$1.54bn
Annual income statement for Wuhan YZY Biopharma Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PRESS | PRESS |
| Standards: | IFRS | — | — |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 134 | 186 | 189 |
| Operating Profit | -134 | -186 | -189 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -149 | -189 | -192 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -149 | -189 | -192 |
| Net Income Before Extraordinary Items | |||
| Net Income | -149 | -189 | -192 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -149 | -189 | -192 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.753 | -1.03 | -0.902 |